{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T01:31:54Z","timestamp":1785807114736,"version":"3.56.0"},"reference-count":117,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2016,6]]},"DOI":"10.1097\/mol.0000000000000291","type":"journal-article","created":{"date-parts":[[2016,3,26]],"date-time":"2016-03-26T20:02:38Z","timestamp":1459022558000},"page":"225-232","source":"Crossref","is-referenced-by-count":34,"title":["Relation between plasma and brain lipids"],"prefix":"10.1097","volume":"27","author":[{"given":"Cheryl L.","family":"Wellington","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruth","family":"Frikke-Schmidt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R2-4-20211004","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1016\/j.bbalip.2010.05.004","article-title":"Lipids in Alzheimer's disease: a century-old story","volume":"1801","author":"Foley","year":"2010","journal-title":"Biochim Biophys Acta"},{"key":"R3-4-20211004","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1515\/BC.2009.035","article-title":"Central nervous system: cholesterol turnover, brain development and neurodegeneration","volume":"390","author":"Dietschy","year":"2009","journal-title":"Biol Chem"},{"key":"R4-4-20211004","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1038\/nrn3012","article-title":"Linking lipids to Alzheimer's disease: cholesterol and beyond","volume":"12","author":"Paolo","year":"2011","journal-title":"Nat Rev Neurosci"},{"key":"R5-4-20211004","first-page":"168","article-title":"Using neurolipidomics to identify phospholipid mediators of synaptic (dys)function in Alzheimer's disease","volume":"4","author":"Bennet","year":"2013","journal-title":"Front Physiol"},{"key":"R6-4-20211004","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1007\/978-3-319-17344-3_3","article-title":"Lipids in amyloid-\u03b2 processing, aggregation, and toxicity","volume":"855","author":"Morgado","year":"2015","journal-title":"Adv Exp Med Biol"},{"key":"R7-4-20211004","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/j.conb.2010.06.008","article-title":"Lipid function at synapses","volume":"20","author":"Davletov","year":"2010","journal-title":"Curr Opin Neurobiol"},{"key":"R8-4-20211004","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1016\/j.bbalip.2014.12.014","article-title":"Brain membrane lipids in major depression and anxiety disorders","volume":"1851","author":"M\u00fcller","year":"2015","journal-title":"Biochim Biophys Acta"},{"key":"R9-4-20211004","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1016\/j.bbalip.2015.01.010","article-title":"Monogenic neurological disorders of spingolipid metabolism","volume":"1851","author":"Sabourdy","year":"2015","journal-title":"Biochim Biophys Acta"},{"key":"R10-4-20211004","doi-asserted-by":"crossref","first-page":"125","DOI":"10.3389\/fendo.2013.00125","article-title":"Lipids in regulated exocytosis: what are they doing?","volume":"4","author":"Ammar","year":"2013","journal-title":"Front Endocrinol"},{"key":"R11-4-20211004","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1042\/BST0340399","article-title":"Lipid dynamics in neurons","volume":"34","author":"Vance","year":"2006","journal-title":"Biochem Soc Trans"},{"key":"R12-4-20211004","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1007\/978-3-319-20825-1_8","article-title":"Endocannabinoids and neurodegenerative disorders: Parkinson's disease, Huntington chorea, Alzheimer's disease, and others","volume":"231","author":"Fern\u00e1ndez-Ruiz","year":"2015","journal-title":"Handb Exp Pharmacol"},{"key":"R13-4-20211004","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1194\/jlr.R400004-JLR200","article-title":"Thematic review series: brain lipids. Cholesterol metabolism in the central nervous system during early development and in the mature animal","volume":"45","author":"Dietschy","year":"2004","journal-title":"J Lipid Res"},{"key":"R14-4-20211004","doi-asserted-by":"crossref","first-page":"891","DOI":"10.3233\/JAD-2012-121585","article-title":"Brain cholesterol metabolism, oxysterols, and dementia","volume":"33","author":"Hughes","year":"2013","journal-title":"J Alzheimers Dis"},{"key":"R15-4-20211004","doi-asserted-by":"crossref","first-page":"7238","DOI":"10.1073\/pnas.96.13.7238","article-title":"cDNA cloning of cholesterol 24-hydroxylase, a mediator of cholesterol homeostasis in the brain","volume":"96","author":"Lund","year":"1999","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R17-4-20211004","doi-asserted-by":"crossref","first-page":"2383","DOI":"10.1093\/brain\/awv166","article-title":"CYP46A1 inhibition, brain cholesterol accumulation and neurodegeneration pave the way for Alzheimer's disease","volume":"138","author":"Djelti","year":"2015","journal-title":"Brain"},{"key":"R18-4-20211004","doi-asserted-by":"crossref","first-page":"5965","DOI":"10.1093\/hmg\/ddv268","article-title":"Cholesterol 24-hydroxylase defect is implicated in memory impairments associated with Alzheimer-like tau pathology","volume":"24","author":"Burlot","year":"2015","journal-title":"Hum Mol Genet"},{"key":"R19-4-20211004","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1038\/nrneurol.2015.119","article-title":"Clearance systems in the brain \u2013 implications for Alzheimer disease","volume":"11","author":"Tarasoff-Conway","year":"2015","journal-title":"Nat Rev Neurol"},{"key":"R20-4-20211004","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1016\/j.cell.2015.10.067","article-title":"Establishment and dysfunction of the blood-brain barrier","volume":"163","author":"Zhao","year":"2015","journal-title":"Cell"},{"key":"R22-4-20211004","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.atherosclerosis.2009.12.027","article-title":"The metabolism of triglyceride-rich lipoproteins revisited: new players, new insight","volume":"211","author":"Dallinga-Thie","year":"2010","journal-title":"Atherosclerosis"},{"key":"R23-4-20211004","doi-asserted-by":"crossref","first-page":"342","DOI":"10.3389\/fphys.2015.00342","article-title":"Kinetic studies to elucidate impaired metabolism of triglyceride-rich lipoproteins in humans","volume":"6","author":"Adiels","year":"2015","journal-title":"Front Physiol"},{"key":"R24-4-20211004","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1093\/cvr\/cvu148","article-title":"HDL and cholesterol handling in the brain","volume":"103","author":"Vitali","year":"2014","journal-title":"Cardiovasc Res"},{"key":"R25-4-20211004","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1016\/j.cmet.2014.01.003","article-title":"High-density lipoproteins and cerebrovascular integrity in Alzheimer's disease","volume":"19","author":"Stukas","year":"2014","journal-title":"Cell Metab"},{"key":"R26-4-20211004","doi-asserted-by":"crossref","first-page":"4646","DOI":"10.1073\/pnas.76.9.4646","article-title":"Apolipoproteins in human cerebrospinal fluid","volume":"76","author":"Roheim","year":"1979","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R27-4-20211004","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.plipres.2014.07.003","article-title":"Understanding high-density lipoprotein function in disease: recent advances in proteomics unravel the complexity of its composition and biology","volume":"56","author":"Birner-Gruenberger","year":"2014","journal-title":"Prog Lipid Res"},{"key":"R28-4-20211004","doi-asserted-by":"crossref","first-page":"2950","DOI":"10.1194\/jlr.R036095","article-title":"Unraveling the complexities of the HDL lipidome","volume":"54","author":"Kontush","year":"2013","journal-title":"J Lipid Res"},{"key":"R29-4-20211004","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.2741\/4170","article-title":"Cerebrospinal fluid biomarkers of Alzheimer's disease in healthy elderly","volume":"18","author":"Randall","year":"2013","journal-title":"Front Biosci"},{"key":"R30-4-20211004","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1586\/epr.12.6","article-title":"The proteomic toolbox for studying cerebrospinal fluid","volume":"9","author":"Van Gool","year":"2012","journal-title":"Expert Rev Proteomics"},{"key":"R31-4-20211004","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1016\/S0022-2275(20)32039-3","article-title":"Characterization and functional studies of lipoproteins, lipid transfer proteins, and lecithin:cholesterol acyltransferase in CSF of normal individuals and patients with Alzheimer's disease","volume":"41","author":"Demeester","year":"2000","journal-title":"J Lipid Res"},{"key":"R32-4-20211004","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1016\/S0022-2275(20)31605-9","article-title":"Characterization of four lipoprotein classes in human cerebrospinal fluid","volume":"42","author":"Koch","year":"2001","journal-title":"J Lipid Res"},{"key":"R33-4-20211004","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1097\/NEN.0000000000000207","article-title":"Cerebrospinal fluid particles in Alzheimer disease and Parkinson disease","volume":"74","author":"Yang","year":"2015","journal-title":"J Neuropathol Exp Neurol"},{"key":"R34-4-20211004","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.3233\/JAD-140141","article-title":"Proteomic analysis of cerebrospinal fluid in Alzheimer's disease: wanted dead or alive","volume":"44","author":"Ol\u00e1h","year":"2015","journal-title":"J Alzheimers Dis"},{"key":"R35-4-20211004","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.jns.2015.12.004","article-title":"Meta-analysis of apolipoprotein E levels in the cerebrospinal fluid of patients with Alzheimer's disease","volume":"360","author":"Talwar","year":"2016","journal-title":"J Neurol Sci"},{"key":"R36-4-20211004","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1111\/j.1749-6632.2000.tb06365.x","article-title":"Lipoproteins in the central nervous system","volume":"903","author":"Ladu","year":"2000","journal-title":"Ann N Y Acad Sci"},{"key":"R37-4-20211004","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1016\/j.bbalip.2010.02.007","article-title":"Formation and function of apolipoprotein E-containing lipoproteins in the nervous system","volume":"1801","author":"Vance","year":"2010","journal-title":"Biochim Biophys Acta"},{"key":"R38-4-20211004","doi-asserted-by":"crossref","first-page":"2070","DOI":"10.1046\/j.1471-4159.1998.70052070.x","article-title":"Nascent astrocyte particles differ from lipoproteins in CSF","volume":"70","author":"LaDu","year":"1998","journal-title":"J Neurochem"},{"key":"R39-4-20211004","doi-asserted-by":"crossref","first-page":"14208","DOI":"10.1074\/jbc.M114.625251","article-title":"Apolipoprotein E inhibits cerebrovascular pericyte mobility through a RhoA protein-mediated pathway","volume":"290","author":"Casey","year":"2015","journal-title":"J Biol Chem"},{"key":"R40-4-20211004","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/S0197-0186(01)00049-3","article-title":"Purification and characterization of astrocyte-secreted apolipoprotein E and J-containing lipoproteins from wild-type and human apoE transgenic mice","volume":"39","author":"DeMattos","year":"2001","journal-title":"Neurochem Int"},{"key":"R41-4-20211004","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1194\/jlr.M014365","article-title":"An ABCA1-independent pathway for recycling a poorly lipidated 8.1\u200anm apolipoprotein E particle from glia","volume":"52","author":"Fan","year":"2011","journal-title":"J Lipid Res"},{"key":"R42-4-20211004","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1194\/jlr.M800584-JLR200","article-title":"LCAT synthesized by primary astrocytes esterifies cholesterol on glia-derived lipoproteins","volume":"50","author":"Hirsch-Reinshagen","year":"2009","journal-title":"J Lipid Res"},{"key":"R43-4-20211004","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/S0304-3940(98)00639-9","article-title":"Pattern of apolipoprotein D immunoreactivity in human brain","volume":"254","author":"Navarro","year":"1998","journal-title":"Neurosci Lett"},{"key":"R44-4-20211004","doi-asserted-by":"crossref","first-page":"1632","DOI":"10.1016\/j.neurobiolaging.2014.01.148","article-title":"Apolipoprotein D takes center stage in the stress response of the aging and degenerative brain","volume":"35","author":"Dassati","year":"2014","journal-title":"Neurobiol Aging"},{"key":"R45-4-20211004","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1046\/j.1471-4159.1994.62020788.x","article-title":"Expression of apolipoprotein A-I in porcine brain endothelium in vitro","volume":"62","author":"M\u00f6ckel","year":"1994","journal-title":"J Neurochem"},{"key":"R47-4-20211004","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.jconrel.2006.11.020","article-title":"Apolipoprotein A-I coating of protamine-oligonucleotide nanoparticles increases particle uptake and transcytosis in an in vitro model of the blood-brain barrier","volume":"117","author":"Kratzer","year":"2007","journal-title":"J Control Release"},{"key":"R48-4-20211004","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1038\/269604a0","article-title":"Polymorphism of apolipoprotein E and occurrence of dysbetalipoproteinemia in man","volume":"269","author":"Utermann","year":"1977","journal-title":"Nature"},{"key":"R49-4-20211004","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1146\/annurev-neuro-071013-014300","article-title":"Apolipoprotein E in Alzheimer's disease: an update","volume":"37","author":"Yu","year":"2014","journal-title":"Annu Rev Neurosci"},{"key":"R50-4-20211004","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1038\/ng.2802","article-title":"Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer's disease","volume":"45","author":"Lambert","year":"2013","journal-title":"Nat Genet"},{"key":"R51-4-20211004","doi-asserted-by":"crossref","first-page":"1716","DOI":"10.1016\/j.bbalip.2014.09.019","article-title":"Fluorescence study of domain structure and lipid interaction of human apolipoproteins E3 and E4","volume":"1841","author":"Mizuguchi","year":"2014","journal-title":"Biochim Biophys Acta"},{"key":"R52-4-20211004","doi-asserted-by":"crossref","first-page":"14813","DOI":"10.1073\/pnas.1106420108","article-title":"Topology of human apolipoprotein E3 uniquely regulates its diverse biological functions","volume":"108","author":"Chen","year":"2011","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R53-4-20211004","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1111\/j.1600-0404.2006.00679.x","article-title":"Apolipoprotein (apo) E4 and Alzheimer's disease: unique conformational and biophysical properties of apoE4 can modulate neuropathology","volume":"185","author":"Mahley","year":"2006","journal-title":"Acta Neurol Scand Suppl"},{"key":"R54-4-20211004","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1016\/j.neuron.2014.01.045","article-title":"ApoE and A\u03b2 in Alzheimer's disease: accidental encounters or partners?","volume":"81","author":"Kanekiyo","year":"2014","journal-title":"Neuron"},{"key":"R55-4-20211004","doi-asserted-by":"crossref","first-page":"a006312","DOI":"10.1101\/cshperspect.a006312","article-title":"Apolipoprotein E and apolipoprotein E receptors: normal biology and roles in Alzheimer disease","volume":"2","author":"Holtzman","year":"2012","journal-title":"Cold Spring Harb Perspect Med"},{"key":"R56-4-20211004","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/S1474-4422(10)70325-2","article-title":"Apolipoprotein E in Alzheimer's disease and other neurological disorders","volume":"10","author":"Verghese","year":"2011","journal-title":"Lancet Neurol"},{"key":"R57-4-20211004","doi-asserted-by":"crossref","first-page":"6323","DOI":"10.1021\/bi5008172","article-title":"The binding of apolipoprotein E to oligomers and fibrils of amyloid-\u03b2 alters the kinetics of amyloid aggregation","volume":"53","author":"Garai","year":"2014","journal-title":"Biochemistry"},{"key":"R58-4-20211004","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1001\/jamaneurol.2013.2152","article-title":"Cerebrovascular effects of apolipoprotein E: implications for Alzheimer disease","volume":"70","author":"Zlokovic","year":"2013","journal-title":"JAMA Neurol"},{"key":"R59-4-20211004","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1038\/nn.4025","article-title":"Central role for PICALM in amyloid-\u03b2 blood-brain barrier transcytosis and clearance","volume":"18","author":"Zhao","year":"2015","journal-title":"Nat Neurosci"},{"key":"R60-4-20211004","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1002\/ana.24326","article-title":"Plasma levels of apolipoprotein E and risk of dementia in the general population","volume":"77","author":"Rasmussen","year":"2015","journal-title":"Ann Neurol"},{"key":"R61-4-20211004","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.neulet.2016.02.018","article-title":"Serum apolipoprotein E is associated with long-term risk of Alzheimer's disease: The Rotterdam Study","volume":"617","author":"Wolters","year":"2016","journal-title":"Neurosci Lett"},{"key":"R62-4-20211004","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1161\/ATVBAHA.112.300749","article-title":"Hyperlipidemia attenuates vascular endothelial growth factor-induced angiogenesis, impairs cerebral blood flow, and disturbs stroke recovery via decreased pericyte coverage of brain endothelial cells","volume":"33","author":"Zechariah","year":"2013","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"R63-4-20211004","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/j.neuron.2010.09.043","article-title":"Pericytes control key neurovascular functions and neuronal phenotype in the adult brain and during brain aging","volume":"68","author":"Bell","year":"2010","journal-title":"Neuron"},{"key":"R64-4-20211004","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.nbd.2014.05.007","article-title":"ATP-binding cassette transporter A1: from metabolism to neurodegeneration","volume":"72","author":"Koldamova","year":"2014","journal-title":"Neurobiol Dis"},{"key":"R65-4-20211004","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1093\/aje\/kwm027","article-title":"The relation between apolipoprotein A-I and dementia: the Honolulu Asia aging study","volume":"165","author":"Saczynski","year":"2007","journal-title":"Am J Epidemiol"},{"key":"R66-4-20211004","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1001\/archneurol.2010.297","article-title":"Association of higher levels of high-density lipoprotein cholesterol in elderly individuals and lower risk of late-onset Alzheimer disease","volume":"67","author":"Reitz","year":"2010","journal-title":"Arch Neurol"},{"key":"R67-4-20211004","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1001\/jamaneurol.2013.5390","article-title":"Associations between serum cholesterol levels and cerebral amyloidosis","volume":"71","author":"Reed","year":"2014","journal-title":"JAMA Neurol"},{"key":"R68-4-20211004","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.jagp.2015.06.004","article-title":"Amyloid-independent amnestic mild cognitive impairment and serum apolipoprotein A1 levels","volume":"24","author":"Choi","year":"2016","journal-title":"Am J Geriatr Psychiatry"},{"key":"R69-4-20211004","doi-asserted-by":"crossref","first-page":"36945","DOI":"10.1074\/jbc.M110.127738","article-title":"Apolipoprotein A-1 deficiency increases cerebral amyloid angiopathy and cognitive deficits in APP\/PS1DeltaE9 mice","volume":"285","author":"Lefterov","year":"2010","journal-title":"J Biol Chem"},{"key":"R70-4-20211004","doi-asserted-by":"crossref","first-page":"36958","DOI":"10.1074\/jbc.M110.127829","article-title":"Overexpression of human apolipoprotein A-I preserves cognitive function and attenuates neuroinflammation and cerebral amyloid angiopathy in a mouse model of Alzheimer disease","volume":"285","author":"Lewis","year":"2010","journal-title":"J Biol Chem"},{"key":"R71-4-20211004","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1093\/cvr\/cvu139","article-title":"High-density lipoproteins as modulators of endothelial cell functions: alterations in patients with coronary artery disease","volume":"103","author":"Kratzer","year":"2014","journal-title":"Cardiovasc Res"},{"key":"R72-4-20211004","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1111\/bph.12174","article-title":"HDL and endothelial protection","volume":"169","author":"Tran-Dinh","year":"2013","journal-title":"Br J Pharmacol"},{"key":"R73-4-20211004","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1002\/biof.1187","article-title":"ABCA1 and nascent HDL biogenesis","volume":"40","author":"Wang","year":"2014","journal-title":"Biofactors"},{"key":"R74-4-20211004","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1002\/biof.37","article-title":"Greasing the wheels of Abeta clearance in Alzheimer's disease: the role of lipids and apolipoprotein E","volume":"35","author":"Fan","year":"2009","journal-title":"Biofactors"},{"key":"R75-4-20211004","doi-asserted-by":"crossref","first-page":"179","DOI":"10.2174\/156720507780362173","article-title":"Liver X receptor-mediated gene regulation and cholesterol homeostasis in brain: relevance to Alzheimer's disease therapeutics","volume":"4","author":"Cao","year":"2007","journal-title":"Curr Alzheimer Res"},{"key":"R76-4-20211004","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1038\/nrd4280","article-title":"Liver X receptors in lipid metabolism: opportunities for drug discovery","volume":"13","author":"Hong","year":"2014","journal-title":"Nat Rev Drug Discov"},{"key":"R77-4-20211004","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/j.neuron.2008.04.010","article-title":"ApoE promotes the proteolytic degradation of Abeta","volume":"58","author":"Jiang","year":"2008","journal-title":"Neuron"},{"key":"R78-4-20211004","doi-asserted-by":"crossref","first-page":"43243","DOI":"10.1074\/jbc.M508781200","article-title":"The absence of ABCA1 decreases soluble ApoE levels but does not diminish amyloid deposition in two murine models of Alzheimer disease","volume":"280","author":"Hirsch-Reinshagen","year":"2005","journal-title":"J Biol Chem"},{"key":"R79-4-20211004","doi-asserted-by":"crossref","first-page":"43236","DOI":"10.1074\/jbc.M508780200","article-title":"Deletion of Abca1 increases Abeta deposition in the PDAPP transgenic mouse model of Alzheimer disease","volume":"280","author":"Wahrle","year":"2005","journal-title":"J Biol Chem"},{"key":"R80-4-20211004","doi-asserted-by":"crossref","first-page":"43224","DOI":"10.1074\/jbc.M504513200","article-title":"Lack of ABCA1 considerably decreases brain ApoE level and increases amyloid deposition in APP23 mice","volume":"280","author":"Koldamova","year":"2005","journal-title":"J Biol Chem"},{"key":"R81-4-20211004","doi-asserted-by":"crossref","first-page":"10601","DOI":"10.1073\/pnas.0701096104","article-title":"Attenuation of neuroinflammation and Alzheimer's disease pathology by liver X receptors","volume":"104","author":"Zelcer","year":"2007","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R82-4-20211004","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1016\/j.jalz.2015.04.006","article-title":"Loss-of-function mutation in ABCA1 and risk of Alzheimer's disease and cerebrovascular disease","volume":"11","author":"Nordestgaard","year":"2015","journal-title":"Alzheimer's Dement"},{"key":"R83-4-20211004","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.brainresrev.2009.05.007","article-title":"Clusterin: a forgotten player in Alzheimer's disease","volume":"61","author":"Nuutinen","year":"2009","journal-title":"Brain Res Rev"},{"key":"R84-4-20211004","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1001\/jama.2011.381","article-title":"Plasma clusterin and the risk of Alzheimer disease","volume":"305","author":"Schrijvers","year":"2011","journal-title":"JAMA"},{"key":"R85-4-20211004","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1093\/bioinformatics\/btp073","article-title":"Meta-analysis of age-related gene expression profiles identifies common signatures of aging","volume":"25","author":"De Magalhaes","year":"2009","journal-title":"Bioinformatics"},{"key":"R86-4-20211004","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1046\/j.1471-4159.1998.71041643.x","article-title":"Increased levels of apolipoprotein D in cerebrospinal fluid and hippocampus of Alzheimer's patients","volume":"71","author":"Terrisse","year":"1998","journal-title":"J Neurochem"},{"key":"R87-4-20211004","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/S0306-4522(03)00529-3","article-title":"Hippocampal apolipoprotein D level depends on Braak stage and APOE genotype","volume":"122","author":"Gl\u00f6ckner","year":"2003","journal-title":"Neuroscience"},{"key":"R88-4-20211004","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1194\/jlr.M700518-JLR200","article-title":"Human apolipoprotein C-I expression in mice impairs learning and memory functions","volume":"49","author":"Abildayeva","year":"2008","journal-title":"J Lipid Res"},{"key":"R89-4-20211004","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1186\/1742-2094-9-192","article-title":"Apolipoprotein C-I is an APOE genotype-dependent suppressor of glial activation","volume":"9","author":"Cudaback","year":"2012","journal-title":"J Neuroinflammation"},{"key":"R90-4-20211004","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1023\/A:1022409617539","article-title":"The apolipoprotein CI A allele as a risk factor for Alzheimer's disease","volume":"23","author":"Poduslo","year":"1998","journal-title":"Neurochem Res"},{"key":"R91-4-20211004","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1212\/WNL.51.1.131","article-title":"Interaction of the apolipoprotein E and CI loci in predisposing to late-onset Alzheimer's disease","volume":"51","author":"Drigalenko","year":"1998","journal-title":"Neurology"},{"key":"R92-4-20211004","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1016\/j.ajpath.2010.11.057","article-title":"Genetic ablation of apolipoprotein A-IV accelerates Alzheimer's disease pathogenesis in a mouse model","volume":"178","author":"Cui","year":"2011","journal-title":"Am J Pathol"},{"key":"R93-4-20211004","doi-asserted-by":"crossref","first-page":"855","DOI":"10.3233\/JAD-140111","article-title":"Apolipoprotein C-III is an amyloid-\u03b2-binding protein and an early marker for Alzheimer's disease","volume":"41","author":"Shih","year":"2014","journal-title":"J Alzheimers Dis"},{"key":"R94-4-20211004","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1016\/j.jalz.2015.05.016","article-title":"Summary of the evidence on modifiable risk factors for cognitive decline and dementia: a population-based perspective","volume":"11","author":"Baumgart","year":"2015","journal-title":"Alzheimer's Dement"},{"key":"R95-4-20211004","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1001\/jamainternmed.2015.2092","article-title":"Statin therapy and risk of acute memory impairment","volume":"175","author":"Strom","year":"2015","journal-title":"JAMA Intern Med"},{"key":"R96-4-20211004","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1212\/01.wnl.0000182897.18229.ec","article-title":"Statins and cognitive function in the elderly: the Cardiovascular Health Study","volume":"65","author":"Bernick","year":"2005","journal-title":"Neurology"},{"key":"R97-4-20211004","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1592\/phco.29.7.800","article-title":"Statin-associated adverse cognitive effects: survey results from 171 patients","volume":"29","author":"Evans","year":"2009","journal-title":"Pharmacotherapy"},{"key":"R98-4-20211004","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1007\/s00415-009-5271-7","article-title":"Pravastatin and cognitive function in the elderly. Results of the PROSPER study","volume":"257","author":"Trompet","year":"2010","journal-title":"J Neurol"},{"key":"R99-4-20211004","doi-asserted-by":"crossref","first-page":"688","DOI":"10.7326\/0003-4819-159-10-201311190-00007","article-title":"Statins and cognitive function: a systematic review","volume":"159","author":"Richardson","year":"2013","journal-title":"Ann Intern Med"},{"key":"R100-4-20211004","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1056\/NEJMoa1500858","article-title":"Efficacy and safety of evolocumab in reducing lipids and cardiovascular events","volume":"372","author":"Sabatine","year":"2015","journal-title":"N Engl J Med"},{"key":"R101-4-20211004","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1056\/NEJMoa1501031","article-title":"Efficacy and safety of alirocumab in reducing lipids and cardiovascular events","volume":"372","author":"Robinson","year":"2015","journal-title":"N Engl J Med"},{"key":"R102-4-20211004","doi-asserted-by":"crossref","first-page":"2638","DOI":"10.1016\/j.jacc.2015.05.001","article-title":"Are PCSK9 inhibitors the next breakthrough in the cardiovascular field?","volume":"65","author":"Giugliano","year":"2015","journal-title":"J Am Coll Cardiol"},{"key":"R103-4-20211004","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1056\/NEJM198711123172001","article-title":"Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease","volume":"317","author":"Frick","year":"1987","journal-title":"N Engl J Med"},{"key":"R104-4-20211004","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1056\/NEJMoa1107579","article-title":"Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy","volume":"365","author":"Boden","year":"2011","journal-title":"N Engl J Med"},{"key":"R105-4-20211004","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1056\/NEJMoa1300955","article-title":"Effects of extended-release niacin with laropiprant in high-risk patients","volume":"371","author":"Landray","year":"2014","journal-title":"N Engl J Med"},{"key":"R106-4-20211004","doi-asserted-by":"crossref","first-page":"2109","DOI":"10.1056\/NEJMoa0706628","article-title":"Effects of torcetrapib in patients at high risk for coronary events","volume":"357","author":"Barter","year":"2007","journal-title":"N Engl J Med"},{"key":"R107-4-20211004","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1056\/NEJMoa1206797","article-title":"Effects of dalcetrapib in patients with a recent acute coronary syndrome","volume":"367","author":"Schwartz","year":"2012","journal-title":"N Engl J Med"},{"key":"R108-4-20211004","doi-asserted-by":"crossref","first-page":"2406","DOI":"10.1056\/NEJMoa1009744","article-title":"Safety of anacetrapib in patients with or at high risk for coronary heart disease","volume":"363","author":"Cannon","year":"2010","journal-title":"N Engl J Med"},{"key":"R109-4-20211004","doi-asserted-by":"crossref","first-page":"2153","DOI":"10.1016\/S0140-6736(14)62115-2","article-title":"Anacetrapib as lipid-modifying therapy in patients with heterozygous familial hypercholesterolaemia (REALIZE): a randomized, double-blind, placebo-controlled, phase 3 study","volume":"385","author":"Kastelein","year":"2015","journal-title":"Lancet"},{"key":"R110-4-20211004","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1001\/jama.2011.1649","article-title":"Effects of the CETP inhibitor evacetrapib administered as monotherapy or in combination with statins on HDL and LDL cholesterol: a randomized controlled trial","volume":"306","author":"Nicholls","year":"2011","journal-title":"JAMA"},{"key":"R111-4-20211004","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1016\/S0140-6736(15)60158-1","article-title":"Cholesterol ester transfer protein inhibition by TA-8995 in patients with mild dyslipidaemia (TULIP): a randomised, double-blind, placebo-controlled phase 2 trial","volume":"386","author":"Hovingh","year":"2015","journal-title":"Lancet"},{"key":"R112-4-20211004","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/S1474-4422(12)70259-4","article-title":"Genetic insights in Alzheimer's disease","volume":"12","author":"Bettens","year":"2013","journal-title":"Lancet Neurol"},{"key":"R113-4-20211004","doi-asserted-by":"crossref","first-page":"223ra20","DOI":"10.1126\/scitranslmed.3007747","article-title":"Lysosomal sorting of amyloid-b by the SORLA receptor is impaired by a familial Alzheimer's disease mutation","volume":"6","author":"Caglayan","year":"2014","journal-title":"Sci Transl Med"},{"key":"R114-4-20211004","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1007\/s12035-014-8742-5","article-title":"The role of SORL1 in Alzheimer's disease","volume":"51","author":"Yin","year":"2015","journal-title":"Mol Neurobiol"},{"key":"R115-4-20211004","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/1750-1326-7-3","article-title":"Both common variations and rare non-synonymous substitutions and small insertion\/deletions in CLU are associated with increased Alzheimer risk","volume":"7","author":"Bettens","year":"2012","journal-title":"Mol Neurodegener"},{"key":"R116-4-20211004","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1002\/ana.24466","article-title":"Rare coding mutations identified by sequencing of Alzheimer disease genome-wide association studies loci","volume":"78","author":"Vardarajan","year":"2015","journal-title":"Ann Neurol"},{"key":"R117-4-20211004","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1038\/ng.3246","article-title":"Loss-of-function variants in ABCA7 confer risk of Alzheimer's disease","volume":"47","author":"Steinberg","year":"2015","journal-title":"Nat Genet"},{"key":"R118-4-20211004","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1016\/S1474-4422(15)00133-7","article-title":"Mutations in ABCA7 in a Belgian cohort of Alzheimer's disease patients: a targeted resequencing study","volume":"14","author":"Cuyvers","year":"2015","journal-title":"Lancet Neurol"},{"key":"R119-4-20211004","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1038\/mp.2012.15","article-title":"High frequency of potentially pathogenic SORL1 mutations in autosomal dominant early-onset Alzheimer disease","volume":"17","author":"Pottier","year":"2012","journal-title":"Mol Psychiatry"},{"key":"R120-4-20211004","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1016\/S0140-6736(15)60461-5","article-title":"A 2 year multidomain intervention of diet, exercise, cognitive training, and vascular risk monitoring versus control to prevent cognitive decline in at-risk elderly people (FINGER): a randomised controlled trial","volume":"385","author":"Ngandu","year":"2015","journal-title":"Lancet"},{"key":"R121-4-20211004","doi-asserted-by":"crossref","first-page":"3673","DOI":"10.1093\/brain\/awv268","article-title":"Common polygenic variation enhances risk prediction for Alzheimer's disease","volume":"138","author":"Escott-Price","year":"2015","journal-title":"Brain"}],"container-title":["Current Opinion in Lipidology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00041433-201606000-00004","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,6]],"date-time":"2021-10-06T18:40:16Z","timestamp":1633545616000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00041433-201606000-00004"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,6]]},"references-count":117,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2016]]}},"URL":"https:\/\/doi.org\/10.1097\/mol.0000000000000291","relation":{},"ISSN":["0957-9672"],"issn-type":[{"value":"0957-9672","type":"print"}],"subject":[],"published":{"date-parts":[[2016,6]]}}}